ArticleFrontiers in pediatrics2025
Identifying neonatal hyperglycemia thresholds in preterm infants based on retinopathy of prematurity outcomes: proof-of-concept study.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Neonatal Hyperglycemia, Risk Factors, and Adverse Outcomes in Extremely Preterm Infants: A Propensity-Matched Cohort Study.Children (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Neonatal hyperglycemia significantly increases risk for retinopathy of prematurity (ROP) in preterm infants, independent of other major ROP risk factors. However, glucose thresholds predictive of ROP remain undefined. This prospective study explored two glycemic metrics-mean blood glucose and glycated hemoglobin [specifically, glycated fetal hemoglobin for non-transfused infants and a neonatal-adapted hemoglobin A1C assay for transfused infants]-to identify thresholds associated with severe ROP. Methods: Infants born at gestational ages <30 weeks and hospitalized at DeVos Children's Hospital (September 2022-August 2024) were eligible. The final cohort included 98 infants. Blood glucose was monitored per clinical care, and glycated hemoglobin was measured on Day 30 using a research prototype assay. Eye exams were conducted per ROP protocol. Predictive thresholds for each biomarker were evaluated using AUC-ROC analysis. Results: Most cases of severe ROP occurred in the transfused participants, who represent the earliest gestational ages and sickest infants. Both glycated hemoglobin (A1C) and 30-day mean blood glucose were significantly higher in infants with severe ROP compared to counterparts with mild or no ROP. Both biomarkers demonstrated concordant positive predictive values of 94%. Predictive cutoffs were identified as 5.66% for A1C ( Conclusions: Severe ROP may represent a clinical outcome for defining neonatal glycemic thresholds. In this pilot study, preliminary cutoffs for two independent glycemic biomarkers are lower than current NICU intervention criteria; further investigation is needed to potentially refine glucose strategies for ROP mitigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.